Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-07-21

AUTHORS

M. Colombié, L. Campion, C. Bailly, D. Rusu, T. Rousseau, C. Mathieu, L. Ferrer, N. Rousseau, F. Kraeber-Bodéré, C. Rousseau

ABSTRACT

PurposeTo evaluate the therapeutic impact of 18F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS).MethodsThis retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 ± 35.0 ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS.ResultsIn 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9 % (41/137) had prostatic recurrence, 42.3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7 % (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6 % (75/172) of the 172 patients. Treatment was changed in 49.6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3 months (95 % CI 18.9 – 45.9 months), according to multivariate analysis age <70 years, SAM ≥23 and SUVmean ≥3 were parameters independently predicting PFS. A nomogram constructed using the three parameters showed 49 months of PFS in patients with the best scores (0 or 1) and only 11 months in patients with a poor score (score 3).ConclusionThis study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC. More... »

PAGES

1784-1793

References to SciGraph publications

  • 2004-10-15. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2009-09-15. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-04-12. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2010-09-17. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-05-01. Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-07-20. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer in WORLD JOURNAL OF UROLOGY
  • 2014-08-15. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-09-12. The age of reason for FDG PET image-derived indices in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-02-22. Comment on Mertens et al.: standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-02-20. [11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-11-27. Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2012-06-15. Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-03-14. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-11-16. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2012-05-02. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging in ANNALS OF NUCLEAR MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-015-3123-5

    DOI

    http://dx.doi.org/10.1007/s00259-015-3123-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1008864359

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/26194716


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Choline", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease-Free Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Follow-Up Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multimodal Imaging", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Positron-Emission Tomography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prostatic Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recurrence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, X-Ray Computed", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.418191.4", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Colombi\u00e9", 
            "givenName": "M.", 
            "id": "sg:person.01241752677.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241752677.61"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France", 
              "id": "http://www.grid.ac/institutes/grid.4817.a", 
              "name": [
                "Statistics, ICO Cancer Center, Saint-Herblain, France", 
                "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Campion", 
            "givenName": "L.", 
            "id": "sg:person.01100327307.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100327307.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.418191.4", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bailly", 
            "givenName": "C.", 
            "id": "sg:person.0665453076.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.418191.4", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rusu", 
            "givenName": "D.", 
            "id": "sg:person.01125524277.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125524277.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Urologic Clinic Nantes-Atlantis, Saint Herblain, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Urologic Clinic Nantes-Atlantis, Saint Herblain, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rousseau", 
            "givenName": "T.", 
            "id": "sg:person.01352534457.70", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352534457.70"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine, University Hospital, Nantes, France", 
              "id": "http://www.grid.ac/institutes/grid.277151.7", 
              "name": [
                "Nuclear Medicine, University Hospital, Nantes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mathieu", 
            "givenName": "C.", 
            "id": "sg:person.01300720363.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300720363.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Physics, ICO Cancer Center, Saint-Herblain, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Physics, ICO Cancer Center, Saint-Herblain, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ferrer", 
            "givenName": "L.", 
            "id": "sg:person.01112242163.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
              "id": "http://www.grid.ac/institutes/grid.418191.4", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rousseau", 
            "givenName": "N.", 
            "id": "sg:person.0632575177.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632575177.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France", 
              "id": "http://www.grid.ac/institutes/grid.4817.a", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
                "Nuclear Medicine, University Hospital, Nantes, France", 
                "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kraeber-Bod\u00e9r\u00e9", 
            "givenName": "F.", 
            "id": "sg:person.0653324404.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France", 
              "id": "http://www.grid.ac/institutes/grid.4817.a", 
              "name": [
                "Nuclear Medicine, Institut de Canc\u00e9rologie de l\u2019Ouest Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France", 
                "Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rousseau", 
            "givenName": "C.", 
            "id": "sg:person.01240530667.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-015-3015-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030966794", 
              "https://doi.org/10.1007/s00259-015-3015-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12149-012-0601-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030375839", 
              "https://doi.org/10.1007/s12149-012-0601-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-012-2083-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005749714", 
              "https://doi.org/10.1007/s00259-012-2083-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2358-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049270716", 
              "https://doi.org/10.1007/s00259-013-2358-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00345-012-0908-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013848464", 
              "https://doi.org/10.1007/s00345-012-0908-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-012-2239-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021666821", 
              "https://doi.org/10.1007/s00259-012-2239-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-009-1253-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021793169", 
              "https://doi.org/10.1007/s00259-009-1253-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1970-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049303071", 
              "https://doi.org/10.1007/s00259-011-1970-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-014-2872-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016743164", 
              "https://doi.org/10.1007/s00259-014-2872-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2364-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038355350", 
              "https://doi.org/10.1007/s00259-013-2364-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-012-2166-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013723636", 
              "https://doi.org/10.1007/s00259-012-2166-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-010-1604-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013594725", 
              "https://doi.org/10.1007/s00259-010-1604-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2421-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050161150", 
              "https://doi.org/10.1007/s00259-013-2421-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00432-012-1354-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043052071", 
              "https://doi.org/10.1007/s00432-012-1354-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-004-1566-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049135908", 
              "https://doi.org/10.1007/s00259-004-1566-1"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2015-07-21", 
        "datePublishedReg": "2015-07-21", 
        "description": "PurposeTo evaluate the therapeutic impact of 18F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS).MethodsThis retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 \u00b1 35.0\u00a0ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS.ResultsIn 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9\u00a0% (41/137) had prostatic recurrence, 42.3\u00a0% (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7\u00a0% (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6\u00a0% (75/172) of the 172 patients. Treatment was changed in 49.6\u00a0% (68/137) of those with a positive FCH PET/CT scan and in 20\u00a0% (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3\u00a0months (95\u00a0% CI 18.9\u00a0\u2013\u00a045.9\u00a0months), according to multivariate analysis age <70\u00a0years, SAM \u226523 and SUVmean \u22653 were parameters independently predicting PFS. A nomogram constructed using the three parameters showed 49\u00a0months of PFS in patients with the best scores (0 or 1) and only 11\u00a0months in patients with a poor score (score 3).ConclusionThis study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00259-015-3123-5", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "12", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "42"
          }
        ], 
        "keywords": [
          "biochemical recurrent prostate cancer", 
          "progression-free survival", 
          "FCH PET/CT scan", 
          "PET/CT scans", 
          "recurrent prostate cancer", 
          "PET/CT", 
          "FCH PET/CT", 
          "prostate cancer", 
          "CT scan", 
          "prostatic recurrence", 
          "distant metastasis", 
          "biochemical recurrence", 
          "PET results", 
          "FCH PET/CT results", 
          "month of PFS", 
          "pelvic lymph node recurrence", 
          "shorter progression-free survival", 
          "PET/CT results", 
          "PET/CT parameters", 
          "lymph node recurrence", 
          "multivariate analysis age", 
          "MethodsThis retrospective study", 
          "locoregional disease", 
          "node recurrence", 
          "consecutive patients", 
          "prostatic bed", 
          "PC patients", 
          "retrospective study", 
          "prognostic value", 
          "clinical variables", 
          "analysis age", 
          "metabolic parameters", 
          "clinical impact", 
          "PET parameters", 
          "FCH PET", 
          "therapeutic strategies", 
          "therapeutic impact", 
          "patients", 
          "CT results", 
          "recurrence", 
          "treatment plan", 
          "ConclusionThis study", 
          "multivariate analysis", 
          "CT parameters", 
          "poorer scores", 
          "CT", 
          "months", 
          "metastasis", 
          "scans", 
          "cancer", 
          "choline kinase activity", 
          "better scores", 
          "scores", 
          "metabolic activity", 
          "kinase activity", 
          "SUVmax", 
          "PurposeTo", 
          "SUVpeak", 
          "disease", 
          "physicians", 
          "nomogram", 
          "PSA", 
          "survival", 
          "age", 
          "treatment", 
          "major impact", 
          "activity", 
          "study", 
          "group", 
          "PET", 
          "years", 
          "uptake", 
          "management", 
          "impact", 
          "factors", 
          "results", 
          "changes", 
          "values", 
          "strategies", 
          "variables", 
          "plan", 
          "bed", 
          "analysis", 
          "parameters", 
          "SAM"
        ], 
        "name": "Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer", 
        "pagination": "1784-1793", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1008864359"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-015-3123-5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "26194716"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-015-3123-5", 
          "https://app.dimensions.ai/details/publication/pub.1008864359"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:33", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_662.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00259-015-3123-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3123-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3123-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3123-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3123-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    339 TRIPLES      21 PREDICATES      139 URIs      116 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-015-3123-5 schema:about N05c11e407ccf4e23a9fd7c18432b1ef6
    2 N3cbd273b6d7f4aa4af92d035730e4a02
    3 N3ed824a0bf864085af879827248693ca
    4 N46198d99975a42799d53a38eab056ea9
    5 N62df782d8e304606b91eea9f4e1574f8
    6 N6c8c4b673f624c4f8ea1258db545851d
    7 N77d43ec00a824816b5137bb878ca315b
    8 N80834fb0d5d64a5aa1dd1a7fb7dd6e2e
    9 N99e737cb17aa4b3ca0fdfa8d54d11c35
    10 N9b4d4810b889434ca5f92d83a710a840
    11 Na589eef5d4d549bdab33a00ac7d09665
    12 Nc97ab59f9c9541148d63776807e64b3a
    13 Nebe9a419af374d24b11cba7459669178
    14 Nf530e3fc200449b1a46b97dc8e7da69b
    15 anzsrc-for:11
    16 anzsrc-for:1112
    17 schema:author N98e91decbf0042998ed7abb56bce003d
    18 schema:citation sg:pub.10.1007/s00259-004-1566-1
    19 sg:pub.10.1007/s00259-009-1253-3
    20 sg:pub.10.1007/s00259-010-1604-0
    21 sg:pub.10.1007/s00259-011-1970-2
    22 sg:pub.10.1007/s00259-012-2083-2
    23 sg:pub.10.1007/s00259-012-2166-0
    24 sg:pub.10.1007/s00259-012-2239-0
    25 sg:pub.10.1007/s00259-013-2358-2
    26 sg:pub.10.1007/s00259-013-2364-4
    27 sg:pub.10.1007/s00259-013-2421-z
    28 sg:pub.10.1007/s00259-014-2872-x
    29 sg:pub.10.1007/s00259-015-3015-8
    30 sg:pub.10.1007/s00345-012-0908-z
    31 sg:pub.10.1007/s00432-012-1354-4
    32 sg:pub.10.1007/s12149-012-0601-8
    33 schema:datePublished 2015-07-21
    34 schema:datePublishedReg 2015-07-21
    35 schema:description PurposeTo evaluate the therapeutic impact of 18F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS).MethodsThis retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 ± 35.0 ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS.ResultsIn 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9 % (41/137) had prostatic recurrence, 42.3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7 % (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6 % (75/172) of the 172 patients. Treatment was changed in 49.6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3 months (95 % CI 18.9 – 45.9 months), according to multivariate analysis age <70 years, SAM ≥23 and SUVmean ≥3 were parameters independently predicting PFS. A nomogram constructed using the three parameters showed 49 months of PFS in patients with the best scores (0 or 1) and only 11 months in patients with a poor score (score 3).ConclusionThis study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC.
    36 schema:genre article
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N4e9fe95212714314850fbdd22748dd82
    39 Nd67be4a2f7b94e398db393df64018ee7
    40 sg:journal.1297401
    41 schema:keywords CT
    42 CT parameters
    43 CT results
    44 CT scan
    45 ConclusionThis study
    46 FCH PET
    47 FCH PET/CT
    48 FCH PET/CT results
    49 FCH PET/CT scan
    50 MethodsThis retrospective study
    51 PC patients
    52 PET
    53 PET parameters
    54 PET results
    55 PET/CT
    56 PET/CT parameters
    57 PET/CT results
    58 PET/CT scans
    59 PSA
    60 PurposeTo
    61 SAM
    62 SUVmax
    63 SUVpeak
    64 activity
    65 age
    66 analysis
    67 analysis age
    68 bed
    69 better scores
    70 biochemical recurrence
    71 biochemical recurrent prostate cancer
    72 cancer
    73 changes
    74 choline kinase activity
    75 clinical impact
    76 clinical variables
    77 consecutive patients
    78 disease
    79 distant metastasis
    80 factors
    81 group
    82 impact
    83 kinase activity
    84 locoregional disease
    85 lymph node recurrence
    86 major impact
    87 management
    88 metabolic activity
    89 metabolic parameters
    90 metastasis
    91 month of PFS
    92 months
    93 multivariate analysis
    94 multivariate analysis age
    95 node recurrence
    96 nomogram
    97 parameters
    98 patients
    99 pelvic lymph node recurrence
    100 physicians
    101 plan
    102 poorer scores
    103 prognostic value
    104 progression-free survival
    105 prostate cancer
    106 prostatic bed
    107 prostatic recurrence
    108 recurrence
    109 recurrent prostate cancer
    110 results
    111 retrospective study
    112 scans
    113 scores
    114 shorter progression-free survival
    115 strategies
    116 study
    117 survival
    118 therapeutic impact
    119 therapeutic strategies
    120 treatment
    121 treatment plan
    122 uptake
    123 values
    124 variables
    125 years
    126 schema:name Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer
    127 schema:pagination 1784-1793
    128 schema:productId N683360f16fa145f7ae533bb5ccdec47b
    129 N6d1e1fb0180544f4973e349afa4672fb
    130 Nd49e0550c64c4c88ba197cd7a349c5dd
    131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008864359
    132 https://doi.org/10.1007/s00259-015-3123-5
    133 schema:sdDatePublished 2022-12-01T06:33
    134 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    135 schema:sdPublisher N0b7d7dd0ccb945049af9ca47366972c2
    136 schema:url https://doi.org/10.1007/s00259-015-3123-5
    137 sgo:license sg:explorer/license/
    138 sgo:sdDataset articles
    139 rdf:type schema:ScholarlyArticle
    140 N05c11e407ccf4e23a9fd7c18432b1ef6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Retrospective Studies
    142 rdf:type schema:DefinedTerm
    143 N0b7d7dd0ccb945049af9ca47366972c2 schema:name Springer Nature - SN SciGraph project
    144 rdf:type schema:Organization
    145 N3cbd273b6d7f4aa4af92d035730e4a02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Multimodal Imaging
    147 rdf:type schema:DefinedTerm
    148 N3ed824a0bf864085af879827248693ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Recurrence
    150 rdf:type schema:DefinedTerm
    151 N46198d99975a42799d53a38eab056ea9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Aged
    153 rdf:type schema:DefinedTerm
    154 N4e9fe95212714314850fbdd22748dd82 schema:issueNumber 12
    155 rdf:type schema:PublicationIssue
    156 N4ee2db61a013421fac513d91a24af99a rdf:first sg:person.01240530667.47
    157 rdf:rest rdf:nil
    158 N53c513cafdba4dee88b72a1d396f39bf rdf:first sg:person.01100327307.34
    159 rdf:rest N64091936ad81453e9293e8b12b50be06
    160 N55e7c3830b8f445aab4f7238d9862b7e rdf:first sg:person.01352534457.70
    161 rdf:rest N6c159c84682047929bde63b31fa934a3
    162 N62df782d8e304606b91eea9f4e1574f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Humans
    164 rdf:type schema:DefinedTerm
    165 N64091936ad81453e9293e8b12b50be06 rdf:first sg:person.0665453076.40
    166 rdf:rest Nb1e94f8a16a843a291eac203c068e242
    167 N683360f16fa145f7ae533bb5ccdec47b schema:name doi
    168 schema:value 10.1007/s00259-015-3123-5
    169 rdf:type schema:PropertyValue
    170 N6c159c84682047929bde63b31fa934a3 rdf:first sg:person.01300720363.95
    171 rdf:rest N9cbc3cbe762946af9d3c4df43bd6afae
    172 N6c8c4b673f624c4f8ea1258db545851d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Aged, 80 and over
    174 rdf:type schema:DefinedTerm
    175 N6d1e1fb0180544f4973e349afa4672fb schema:name pubmed_id
    176 schema:value 26194716
    177 rdf:type schema:PropertyValue
    178 N77d43ec00a824816b5137bb878ca315b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Choline
    180 rdf:type schema:DefinedTerm
    181 N80834fb0d5d64a5aa1dd1a7fb7dd6e2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Male
    183 rdf:type schema:DefinedTerm
    184 N98e91decbf0042998ed7abb56bce003d rdf:first sg:person.01241752677.61
    185 rdf:rest N53c513cafdba4dee88b72a1d396f39bf
    186 N99e737cb17aa4b3ca0fdfa8d54d11c35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Disease-Free Survival
    188 rdf:type schema:DefinedTerm
    189 N9b4d4810b889434ca5f92d83a710a840 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Middle Aged
    191 rdf:type schema:DefinedTerm
    192 N9cbc3cbe762946af9d3c4df43bd6afae rdf:first sg:person.01112242163.57
    193 rdf:rest Nf14a7d8ddb704f4e981ed6c72d116997
    194 Na589eef5d4d549bdab33a00ac7d09665 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Positron-Emission Tomography
    196 rdf:type schema:DefinedTerm
    197 Nb1e94f8a16a843a291eac203c068e242 rdf:first sg:person.01125524277.32
    198 rdf:rest N55e7c3830b8f445aab4f7238d9862b7e
    199 Nc97ab59f9c9541148d63776807e64b3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Tomography, X-Ray Computed
    201 rdf:type schema:DefinedTerm
    202 Nd480fa8e035d446ba3aa7b79f8446cf5 rdf:first sg:person.0653324404.03
    203 rdf:rest N4ee2db61a013421fac513d91a24af99a
    204 Nd49e0550c64c4c88ba197cd7a349c5dd schema:name dimensions_id
    205 schema:value pub.1008864359
    206 rdf:type schema:PropertyValue
    207 Nd67be4a2f7b94e398db393df64018ee7 schema:volumeNumber 42
    208 rdf:type schema:PublicationVolume
    209 Nebe9a419af374d24b11cba7459669178 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Prostatic Neoplasms
    211 rdf:type schema:DefinedTerm
    212 Nf14a7d8ddb704f4e981ed6c72d116997 rdf:first sg:person.0632575177.48
    213 rdf:rest Nd480fa8e035d446ba3aa7b79f8446cf5
    214 Nf530e3fc200449b1a46b97dc8e7da69b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    215 schema:name Follow-Up Studies
    216 rdf:type schema:DefinedTerm
    217 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    218 schema:name Medical and Health Sciences
    219 rdf:type schema:DefinedTerm
    220 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    221 schema:name Oncology and Carcinogenesis
    222 rdf:type schema:DefinedTerm
    223 sg:journal.1297401 schema:issn 1619-7070
    224 1619-7089
    225 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    226 schema:publisher Springer Nature
    227 rdf:type schema:Periodical
    228 sg:person.01100327307.34 schema:affiliation grid-institutes:grid.4817.a
    229 schema:familyName Campion
    230 schema:givenName L.
    231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100327307.34
    232 rdf:type schema:Person
    233 sg:person.01112242163.57 schema:affiliation grid-institutes:None
    234 schema:familyName Ferrer
    235 schema:givenName L.
    236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112242163.57
    237 rdf:type schema:Person
    238 sg:person.01125524277.32 schema:affiliation grid-institutes:grid.418191.4
    239 schema:familyName Rusu
    240 schema:givenName D.
    241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125524277.32
    242 rdf:type schema:Person
    243 sg:person.01240530667.47 schema:affiliation grid-institutes:grid.4817.a
    244 schema:familyName Rousseau
    245 schema:givenName C.
    246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
    247 rdf:type schema:Person
    248 sg:person.01241752677.61 schema:affiliation grid-institutes:grid.418191.4
    249 schema:familyName Colombié
    250 schema:givenName M.
    251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241752677.61
    252 rdf:type schema:Person
    253 sg:person.01300720363.95 schema:affiliation grid-institutes:grid.277151.7
    254 schema:familyName Mathieu
    255 schema:givenName C.
    256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300720363.95
    257 rdf:type schema:Person
    258 sg:person.01352534457.70 schema:affiliation grid-institutes:None
    259 schema:familyName Rousseau
    260 schema:givenName T.
    261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352534457.70
    262 rdf:type schema:Person
    263 sg:person.0632575177.48 schema:affiliation grid-institutes:grid.418191.4
    264 schema:familyName Rousseau
    265 schema:givenName N.
    266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632575177.48
    267 rdf:type schema:Person
    268 sg:person.0653324404.03 schema:affiliation grid-institutes:grid.4817.a
    269 schema:familyName Kraeber-Bodéré
    270 schema:givenName F.
    271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
    272 rdf:type schema:Person
    273 sg:person.0665453076.40 schema:affiliation grid-institutes:grid.418191.4
    274 schema:familyName Bailly
    275 schema:givenName C.
    276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40
    277 rdf:type schema:Person
    278 sg:pub.10.1007/s00259-004-1566-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049135908
    279 https://doi.org/10.1007/s00259-004-1566-1
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1007/s00259-009-1253-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021793169
    282 https://doi.org/10.1007/s00259-009-1253-3
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1007/s00259-010-1604-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013594725
    285 https://doi.org/10.1007/s00259-010-1604-0
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1007/s00259-011-1970-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049303071
    288 https://doi.org/10.1007/s00259-011-1970-2
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1007/s00259-012-2083-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005749714
    291 https://doi.org/10.1007/s00259-012-2083-2
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1007/s00259-012-2166-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013723636
    294 https://doi.org/10.1007/s00259-012-2166-0
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1007/s00259-012-2239-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021666821
    297 https://doi.org/10.1007/s00259-012-2239-0
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1007/s00259-013-2358-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049270716
    300 https://doi.org/10.1007/s00259-013-2358-2
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1007/s00259-013-2364-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038355350
    303 https://doi.org/10.1007/s00259-013-2364-4
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1007/s00259-013-2421-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1050161150
    306 https://doi.org/10.1007/s00259-013-2421-z
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1007/s00259-014-2872-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016743164
    309 https://doi.org/10.1007/s00259-014-2872-x
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1007/s00259-015-3015-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030966794
    312 https://doi.org/10.1007/s00259-015-3015-8
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1007/s00345-012-0908-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1013848464
    315 https://doi.org/10.1007/s00345-012-0908-z
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.1007/s00432-012-1354-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043052071
    318 https://doi.org/10.1007/s00432-012-1354-4
    319 rdf:type schema:CreativeWork
    320 sg:pub.10.1007/s12149-012-0601-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030375839
    321 https://doi.org/10.1007/s12149-012-0601-8
    322 rdf:type schema:CreativeWork
    323 grid-institutes:None schema:alternateName Physics, ICO Cancer Center, Saint-Herblain, France
    324 Urologic Clinic Nantes-Atlantis, Saint Herblain, France
    325 schema:name Physics, ICO Cancer Center, Saint-Herblain, France
    326 Urologic Clinic Nantes-Atlantis, Saint Herblain, France
    327 rdf:type schema:Organization
    328 grid-institutes:grid.277151.7 schema:alternateName Nuclear Medicine, University Hospital, Nantes, France
    329 schema:name Nuclear Medicine, University Hospital, Nantes, France
    330 rdf:type schema:Organization
    331 grid-institutes:grid.418191.4 schema:alternateName Nuclear Medicine, Institut de Cancérologie de l’Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France
    332 schema:name Nuclear Medicine, Institut de Cancérologie de l’Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France
    333 rdf:type schema:Organization
    334 grid-institutes:grid.4817.a schema:alternateName Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France
    335 schema:name Nantes-Angers Cancer Research Center, INSERM U892-CNRS UMR 6299, Nantes University, Nantes, France
    336 Nuclear Medicine, Institut de Cancérologie de l’Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France
    337 Nuclear Medicine, University Hospital, Nantes, France
    338 Statistics, ICO Cancer Center, Saint-Herblain, France
    339 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...